Clinical trial · Interventional
Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients
Development and Application of an Artificial Intelligence Chatbot for Perioperative Health Education Among Thyroid Cancer Patients: A Quasi-Experimental Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to evaluate the usefulness and effectiveness of a newly developed artificial intelligence (AI) chatbot for health education in thyroid cancer patients during the period around their surgery (the perioperative period). The main questions it aims to answer are: Does the AI chatbot improve patients' readiness for discharge, quality of recovery, and active engagement in their own healthcare compared to traditional education methods? How do patients rate the usability and friendliness of this new AI chatbot system? Researchers will compare a group of patients who receive traditional health education (the control group) with a subsequent group of patients who use the new AI chatbot built on the "Coze" platform (the intervention group) to see if the AI chatbot leads to better recovery experiences and higher patient engagement. Participants will be asked to: Access and interact with the AI chatbot to receive personalized health guidance, ask questions, and get instant feedback during their hospital stay. Complete a set of questionnaires on the morning of their hospital discharge to evaluate their recovery quality, readiness to leave the hospital, and level of engagement in their care. Complete an extra survey regarding the usability and acceptability of the chatbot system (only for participants in the AI chatbot group).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Coze-Based AI Chatbot Health Education | Behavioral | — | UNRESOLVED |
| Routine Perioperative Health Education | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Control Phase: Routine Health Education
- interventionNames
- Behavioral: Routine Perioperative Health Education
- type
- EXPERIMENTAL
- label
- Intervention Phase: Coze-Based AI Chatbot
- interventionNames
- Behavioral: Coze-Based AI Chatbot Health Education
Primary outcomes (3)
- measure
- Readiness for Hospital Discharge
- timeFrame
- On the morning of hospital discharge
- description
- Measured using the Readiness for Hospital Discharge Scale (RHDS). The scale consists of 23 items across four dimensions: personal status (7 items), knowledge of the disease (8 items), coping ability (3 items), and expected support (4 items). Each item is scored on a 0-10 scale. The total score ranges from 0 to 220, with higher scores indicating a higher and more sufficient readiness for hospital discharge. The overall Cronbach's alpha of the scale is 0.97.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with thyroid cancer in accordance with the clinical diagnostic criteria, and confirmed by ultrasonography and histopathological examination. * Scheduled to undergo elective surgery for thyroid cancer. * Mentally competent to understand the study protocol, and voluntarily provided written informed consent to participate in this study. Exclusion Criteria: * Aged less than 18 years. * Concurrently diagnosed with malignant tumors in other organs or severe complications/dysfunctions of other major organs. * Patients who are anticipated to be unable to complete the study protocol due to plans for hospital/department transfer, or high risk of treatment discontinuation.
References
Publications (0)
Data not yet available